Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
16.04
-0.33 (-2.02%)
At close: Apr 28, 2026, 4:00 PM EDT
16.10
+0.06 (0.35%)
After-hours: Apr 28, 2026, 4:40 PM EDT
Aurinia Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Aurinia Pharmaceuticals stock have an average target of 17.25, with a low estimate of 15 and a high estimate of 21. The average target predicts an increase of 7.54% from the current stock price of 16.04.
Analyst Consensus: Buy
* Price targets were last updated on Dec 3, 2025.
Analyst Ratings
The average analyst rating for Aurinia Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $15 → $16 | Buy → Hold | Downgrades | $15 → $16 | -0.25% | Dec 3, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $10 → $21 | Hold → Strong Buy | Upgrades | $10 → $21 | +30.92% | Nov 7, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $9 → $15 | Buy → Hold | Downgrades | $9 → $15 | -6.48% | Nov 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $8 → $9 | Buy | Maintains | $8 → $9 | -43.89% | Aug 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +5.99% | Jul 30, 2025 |
Financial Forecast
Revenue This Year
332.71M
from 283.06M
Increased by 17.54%
Revenue Next Year
385.09M
from 332.71M
Increased by 15.74%
EPS This Year
0.81
from 2.07
Decreased by -60.97%
EPS Next Year
1.07
from 0.81
Increased by 32.32%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 360.7M | 478.2M | ||||||
| Avg | 332.7M | 385.1M | ||||||
| Low | 313.6M | 352.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 27.4% | 43.7% | ||||||
| Avg | 17.5% | 15.7% | ||||||
| Low | 10.8% | 6.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.98 | 1.65 | ||||||
| Avg | 0.81 | 1.07 | ||||||
| Low | 0.67 | 0.55 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -52.8% | 104.1% | ||||||
| Avg | -61.0% | 32.3% | ||||||
| Low | -67.8% | -32.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.